Related Experiment Videos
Recombinant Hev b 1: large-scale production and immunological characterization
H P Rihs1, Z Chen, S Schumacher
1Research Institute for Occupational Medicine (BGFA), Bochum, Germany.
Summary
Recombinant Hev b 1 (rHev b 1) produced via fusion protein methods demonstrates comparable IgE-binding to natural Hev b 1 (nHev b 1). This rHev b 1 is suitable for latex allergy diagnostics and research, overcoming limitations of native allergen availability.
Area of Science:
- Allergen research
- Immunology
- Biotechnology
Background:
- Hev b 1 is a primary allergen in Hevea brasiliensis latex.
- Obtaining sufficient native Hev b 1 (nHev b 1) for research is challenging.
Purpose of the Study:
- To produce adequate Hev b 1 using recombinant DNA technology.
- To validate the utility of recombinant Hev b 1 (rHev b 1) in latex allergy diagnostics.
Main Methods:
- Synthesized cDNA from Hevea brasiliensis leaves.
- Expressed recombinant Hev b 1 (rHev b 1) and fragments as Maltose-binding protein (MBP) fusion proteins in E. coli.
- Evaluated MBP-rHev b 1 using CAP-RAST, histamine release tests, and immunoblots with human sera and monoclonal antibodies.
Main Results:
- MBP-rHev b 1 fusion protein showed high allergenicity.
- 93% of latex-sensitized spina bifida patients' sera and 22.5% of latex-allergic healthcare workers' sera exhibited IgE-binding to rHev b 1.
- N-terminal deletions up to residue 28 did not affect IgE-binding; larger deletions reduced or abolished binding.
Conclusions:
- Recombinant Hev b 1 (rHev b 1) fusion protein displays IgE-binding reactivity similar to nHev b 1.
- rHev b 1 can serve as a substitute for nHev b 1 in in vitro diagnostics and research applications.